Skip to main content

Advertisement

Table 2 Health care resource use by line of therapy and regimen in Japan, Korea, Taiwan, and Brazil

From: Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study

  Japan Korea Taiwan Brazil
(N = 175) (N = 150) (N = 217) (N = 175)
Characteristic N a Inpatient stayb Outpatient visit N a Inpatient stay Outpatient visit N a Inpatient stay Outpatient visit N a Inpatient stay Outpatient visit
First-line therapy 134 109 (81) 117 (87) 134 83 (62) 130 (97) 172 94 (55) 149 (87) 106 33 (31) 94 (89)
 Platinum-based comb. 94 84 (89) 79 (84) 107 67 (63) 103 (96) 33 26 (79) 24 (73) 100 30 (30) 89 (89)
 Non-platinum comb. 0 0 0 0 0 0 26 17 (65) 24 (92) 0 0 0
 Single agent 10 6 (60) 9 (90) 3 3 (100) 3 (100) 29 7 (24) 28 (97) 2 1 (50) 1 (50)
 EGFR/ALK TKI 30 19 (63) 29 (97) 24 13 (54) 24 (100) 84 44 (52) 73 (87) 4 2 (50) 4 (100)
Second-line therapy 89 75 (84) 81 (91) 93 62 (67) 90 (97) 131 70 (53) 112 (86) 63 22 (35) 57 (90)
 Platinum-based comb. 22 17 (77) 17 (77) 11 6 (55) 11 (100) 35 25 (71) 24 (69) 7 1 (14) 7 (100)
 Non-platinum comb. 2 2 (100) 2 (100) 3 3 (100) 2 (67) 30 10 (33) 30 (100) 1 1 (100) 1 (100)
 Single agent 48 42 (88) 47 (98) 31 21 (68) 31 (100) 40 22 (55) 36 (90) 50 18 (36) 44 (88)
 EGFR/ALK TKI 17 14 (82) 15 (88) 48 32 (67) 46 (96) 26 13 (50) 22 (85) 5 2 (40) 5 (100)
  1. Data are n (%) unless otherwise noted
  2. aN represents patients with available HCRU data
  3. bAn inpatient stay was defined as one or more nights in a hospital or hospice
  4. ALK anaplastic lymphoma kinase, comb. combination, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor